CMS Proposes Approval of Additional Payment for Sequana Medical’s alfapump® system in Hospital Inpatient Cases New Technology Add-on Payment ...

Sequana Medical announced today that CMS recommended that its Alfapump system become eligible for a new incremental payment.

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 8 April 2025 - Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical") ...

Following positive data reported earlier this year from a Phase I/II trial, Sequana Medical has touted results from a study showing its device’s superiority in clearing sodium versus traditional ...

Ghent, Belgium – 18 March 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart ...

The US Food and Drug Administration (FDA) has approved Sequana Medical’s alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis. The agency’s greenlight makes ...

Ghent, Belgium – 14 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA, the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart ...

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 8 April 2025 – Sequana Medical NV (Euronext ...

CMS proposes approval of additional payment for Sequana Medical’s alfapump system in hospital inpatient cases: Ghent, Belgium Tuesday, April 15, 2025, 17:00 Hrs [IST] Sequana Me ...

Ghent, Belgium, 8 April 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure ...